MVision GDPR compliant SaaS segmentation service obtained CE certification for all major cancer sites

MVision AI OY, a Helsinki based startup company in the field of radiation oncology software services, announces the successful CE certification of all AI-based organ models. The latest version of its innovative cloud-based segmentation services offers now organ models for all major cancer sites.

The different models can be used to automatically contour organs at risk and target structures in the brain, head & neck, male and female thorax, abdomen, and female and male pelvis regions. The deep learning neural network has been trained using ground truth data following internationally accepted consensus guidelines and can be used by any clinic without further training or adaptation by user-specific data.

Mahmudul Hasan, founder, and CEO of MVision AI says: “I am very proud of the whole team at MVision AI who has done a tremendous job in creating such a strong service in quite a short time. I am very thankful to our clinical collaboration partners for all discussions and feedback we got from them” Mahmudul Hasan continued: “The CE certification and clinical release of our first complete set of organ models marks a major milestone for the company and is a strong base for the development of new MVision services and products. We are working with our clinical partners on AI-based MRI contouring and on AI-driven dose prediction for different treatment modalities. It is just the first step to MVision’s cloud-based Physician Driven Planning Solution. In parallel, we are building a strong distribution network and will be happy to announce in the coming weeks the global growth of our partner network.”

About MVision AI

MVision AI is a young Helsinki based medical technology startup developing innovative AI-based software as a service solution to improve radiation oncology. The company has started marketing MVision Segmentation Services earlier this year. Already today, clinics in five European countries are using MVision’s cloud-based services on a regular base. This year MVision will focus on the European markets and will enter the international markets namely in the US and APAC later part next year.

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts


World Kidney Cancer Day 2024: “Listen”

World Kidney Cancer Day is observed every year on the second Thursday of June. “Listening” is this year’s theme, which refers to the benefits of shared decision making, patient’s empowerment to seek a second opinion and creating awareness around misinformation and how to check if sources are reliable (1). More…



MVision AI Appoints Antti Pirskanen as New Chief Financial Officer

Helsinki, Finland – June 14, 2024 – MVision AI, a pioneering company in the development of innovative AI solutions for radiation oncology is pleased to announce the appointment of Antti Pirskanen as its new Chief Financial Officer (CFO). Antti will assume his responsibilities immediately, bringing extensive expertise in financial management…

Press Releases


MVision AI Receives MFDS Approval and Market Authorization for South Korea

HELSINKI, Finland – June 14, 2024 MVision AI is pleased to announce that our application for MVision AI Segmentation (Contour+) in South Korea has been accepted by the Ministry of Food and Drug Safety (MFDS) under the “Image Segmentation Application Software” for image analysis algorithms to be used in radiation…

Press Releases